GlassScriptPhysician profile
Joel Alack
NPI 1568968196
$1,108.94
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.55 · 2022: $182 · 2023: $437 · 2024: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $283.06 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.88 | 2021-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.56 | 2022-2024 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $163.90 | 2024 | Ultomiris |
| Pfizer INC. | $134.60 | 2022-2024 | |
| Inari Medical, INC. | $42.70 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $30.12 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $26.30 | 2021-2022 | |
| Novo Nordisk INC | $22.77 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $20.92 | 2023 | |
| Mallinckrodt Hospital Products INC. | $18.97 | 2024 | Terlivaz |
| Abbvie INC. | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Alack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.